AI specialist NVIDIA and Danish pharmaceutical company Novo Nordisk are working together to accelerate drug development with the help of artificial intelligence.
The Danish pharmaceutical manufacturer $NOVO B (-3,27 %) and the AI specialist $NVDA (-0,15 %) are working together to accelerate drug development with the help of artificial intelligence.
This is being done in collaboration with the Danish Center for AI Innovation DCAI, which has an AI supercomputer from NVIDIA that will be used for this purpose.
In their collaboration, the two companies aim to develop customized AI models and agents that can then be used by Novo Nordisk for early research and clinical development. Use for advanced simulations and physical AI technologies is also possible
